Qiagen Rating Lowered to Market Perform at Leerink (QGEN)
Qiagen (NASDAQ: QGEN) was downgraded by analysts at Leerink from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday.
Separately, analysts at Mizuho raised their price target on shares of Qiagen from $15.00 to $17.00 in a research note to investors on Thursday. They now have a “neutral” rating on the stock.
Shares of Qiagen traded down 0.18% during mid-day trading on Friday, hitting $16.55. Qiagen has a 52 week low of $12.47 and a 52 week high of $22.20. The company has a market cap of $3.877 billion and a P/E ratio of 41.45.
The company last announced its quarterly results on Wednesday, April 25th. It reported $0.23 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.21 EPS by $0.02. The company’s quarterly revenue was up 12.1% on a year-over-year basis. On average, analysts predict that Qiagen will post $0.23 earnings per share next quarter.
QIAGEN N.V. is a holding company, which provides technologies and products for preanalytical sample preparation and linked molecular assay solutions.